Russia's R-Pharm links with Rosatom on production

Russian nuclear monopoly firm Rosatom Healthcare has joined forces with one of the country’s leading drugmakers R-Pharm, to invest 10 billion roubles ($147 million) in the establishment of joint production of drugs in Moscow this year, according to the companies.

An official spokesman of Rosatom, a pharmaceutical arm of the company, said the sides are planning to launch a wide range of drugs, some of which will be innovative and will have no analogues in the world, reports The Pharma Letter’s local correspondent.

According to head of R-Pharm Alexey Repik, to date, the companies have already completed the design of the enterprise and are ready to start construction works.